Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349868 · ClinicalTrials.gov registry record · Phase 2
PT005 MDI Dose Ranging Versus Foradil Aerolizer Study
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01349868 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT01349868, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG PT005 MDI
- DRUG Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
- OTHER Placebo MDI
- DRUG Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349868
The ClinicalTrials.gov registry entry for NCT01349868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PT005 MDI is the first listed.
NCT01349868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349868 about?
NCT01349868 is a clinical study titled "PT005 MDI Dose Ranging Versus Foradil Aerolizer Study". The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT01349868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2011-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01349868?
The interventions under investigation include: PT005 MDI (DRUG), Formoterol Fumarate 12 μg (Foradil® Aerolizer®) (DRUG), Placebo MDI (OTHER), Formoterol Fumarate 24 μg (Foradil® Aerolizer®) (DRUG).
Who is sponsoring clinical trial NCT01349868?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.